BioCentury | Oct 30, 2020

Via takeout of Atlas-grown optogenetic play for $150M up front, Novartis adds to gene therapy arsenal

Novartis’ acquisition of Atlas-incubated start-up Vedere Bio will bolster an ophthalmic gene therapy portfolio spearheaded by Luxturna, and will give the Swiss pharma technology to deliver gene therapies to the retina intravitreally.  Novartis AG (NYSE:NVS; SIX:NOVN)...
BioCentury | Oct 24, 2020
Emerging Company Profile

SparingVision’s line of sight to a mutation-agnostic gene therapy for ophthalmic disease

SparingVision thinks its neuroprotective AAV therapy could benefit all retinitis pigmentosa patients, including those missed by mutation-targeted gene replacement therapies like Luxturna. The Paris-based...
BioCentury | Sep 24, 2019
Company News

Cigna eases burden of high cost gene therapies; plan doesn’t account for lack of benefit

As the Medicaid best price rule continues to stymie attempts to move beyond one-time payments for gene therapies, some payers and pharmacy benefit managers are working to soften the blow for their clients and patients....
BioCentury | Sep 4, 2019
Company News

Novartis’ early collaboration with NICE key to rapid response on Luxturna

In one of NICE’s fastest draft recommendations for a new therapy on the NHS, the HTA found gene therapy Luxturna from Novartis to be cost-effective to treat a rare genetic retinal disorder. Novartis’ offer of...
BioCentury | Jun 27, 2019
Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

As in vivo gene therapies continue notching approvals for rare monogenic diseases, the next frontier for the modality will be in treating complex indications without obvious genetic drivers. At least seven companies have clinical or...
BioCentury | Jun 17, 2019
Company News

Trial data suggest 80% of Zynteglo patients could meet milestones in outcomes-based pricing model

The most recent long-term data for bluebird bio's Zynteglo β thalassemia gene therapy show that about 80% of patients could hit payment milestones based on details the biotech disclosed about its outcomes-based pricing model on...
BioCentury | May 18, 2019
Product Development

AAVs on the brink: Charting the clinical landscape of in vivo gene therapies

Gene therapy is finally teetering on the edge of becoming a drug development mainstay, with at least nine AAV-based therapies in Phase III or II/III testing. An analysis of the AAV therapies in the clinic...
BioCentury | Apr 26, 2019
Product Development

Rise of the independents, biotechs go to market

While product launch and commercialization has largely been the province of big biotech and big pharma, with smaller companies partnering to get their products over the finish line, BioCentury’s analysis of recent FDA approvals finds...
BioCentury | Apr 4, 2019
Translation in Brief

Promoting AAV vectors to safety

...Sciences , the team reported that a cytomegalovirus (CMV) promoter, a human retinal pigment epithelial (RPE)-specific...
BioCentury | Mar 2, 2019
Product Development

Roche broadens its BD scope

Roche’s proposed acquisition of Spark Therapeutics Inc. is the pharma’s first major deal since James Sabry took over partnering, and could be a glimpse of what’s to come as the pharma broadens its horizons on...
Items per page:
1 - 10 of 231